October Pharma S.A.E (EGX: OCPH)
Egypt
· Delayed Price · Currency is EGP 108.23
0.00 (0.00%)
At close: Nov 20, 2024
October Pharma S.A.E Income Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 1,193 | 1,012 | 727.37 | 655.04 | 543.4 | 523.11 | Upgrade
|
| Revenue Growth (YoY) | 33.93% | 39.08% | 11.04% | 20.54% | 3.88% | 30.55% | Upgrade
|
| Cost of Revenue | -285.79 | 515.09 | 375.34 | 331.75 | 291.86 | 308.45 | Upgrade
|
| Gross Profit | 1,479 | 496.56 | 352.03 | 323.29 | 251.54 | 214.66 | Upgrade
|
| Selling, General & Admin | 172.54 | 164.4 | 139.53 | 121.93 | 97.71 | 113.3 | Upgrade
|
| Other Operating Expenses | 28.13 | 18.98 | 10.67 | 3.61 | 1.08 | 2.95 | Upgrade
|
| Operating Expenses | 191.8 | 189.5 | 152.8 | 127.75 | 106.49 | 116.24 | Upgrade
|
| Operating Income | 1,287 | 307.06 | 199.23 | 195.54 | 145.04 | 98.42 | Upgrade
|
| Interest Expense | -112.32 | -62.77 | -27.7 | -30.2 | -31.91 | -48.41 | Upgrade
|
| Currency Exchange Gain (Loss) | 14.27 | 0.17 | 1.61 | -0.7 | 0.02 | -3.18 | Upgrade
|
| Other Non Operating Income (Expenses) | -956.9 | - | - | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | 232.22 | 244.45 | 173.14 | 164.65 | 113.16 | 46.83 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.64 | 0.24 | 0.34 | - | 0.05 | 0.14 | Upgrade
|
| Pretax Income | 232.87 | 244.69 | 173.48 | 164.65 | 113.21 | 46.97 | Upgrade
|
| Income Tax Expense | 16.69 | 62.56 | 42.74 | 44.85 | 24.95 | 13.14 | Upgrade
|
| Net Income | 216.18 | 182.13 | 130.75 | 119.79 | 88.26 | 33.83 | Upgrade
|
| Preferred Dividends & Other Adjustments | 31.73 | 31.73 | 17.02 | - | - | - | Upgrade
|
| Net Income to Common | 184.44 | 150.4 | 113.73 | 119.79 | 88.26 | 33.83 | Upgrade
|
| Net Income Growth | -66.88% | 39.30% | 9.15% | 35.73% | 160.91% | 84.61% | Upgrade
|
| Shares Outstanding (Basic) | 21 | 12 | 12 | 12 | 12 | 12 | Upgrade
|
| Shares Outstanding (Diluted) | 21 | 12 | 12 | 12 | 12 | 12 | Upgrade
|
| Shares Change (YoY) | -55.51% | - | - | - | - | - | Upgrade
|
| EPS (Basic) | 8.93 | 12.53 | 9.48 | 9.98 | 7.35 | 2.82 | Upgrade
|
| EPS (Diluted) | 8.93 | 12.53 | 9.48 | 9.98 | 7.35 | 2.82 | Upgrade
|
| EPS Growth | -36.72% | 32.24% | -5.06% | 35.73% | 160.91% | 84.61% | Upgrade
|
| Free Cash Flow | 61.8 | 117.56 | -185 | 242.43 | 47.65 | 62.83 | Upgrade
|
| Free Cash Flow Per Share | 2.99 | 9.80 | -15.42 | 20.20 | 3.97 | 5.24 | Upgrade
|
| Dividend Per Share | 2.500 | 2.500 | - | - | 1.500 | - | Upgrade
|
| Gross Margin | 123.95% | 49.08% | 48.40% | 49.35% | 46.29% | 41.04% | Upgrade
|
| Operating Margin | 107.88% | 30.35% | 27.39% | 29.85% | 26.69% | 18.81% | Upgrade
|
| Profit Margin | 15.46% | 14.87% | 15.64% | 18.29% | 16.24% | 6.47% | Upgrade
|
| Free Cash Flow Margin | 5.18% | 11.62% | -25.43% | 37.01% | 8.77% | 12.01% | Upgrade
|
| EBITDA | 1,309 | 329.17 | 221.23 | 216.34 | 163.87 | 115.04 | Upgrade
|
| EBITDA Margin | 109.71% | 32.54% | 30.41% | 33.03% | 30.16% | 21.99% | Upgrade
|
| D&A For EBITDA | 21.85 | 22.11 | 22 | 20.8 | 18.82 | 16.63 | Upgrade
|
| EBIT | 1,287 | 307.06 | 199.23 | 195.54 | 145.04 | 98.42 | Upgrade
|
| EBIT Margin | 107.88% | 30.35% | 27.39% | 29.85% | 26.69% | 18.81% | Upgrade
|
| Effective Tax Rate | 7.17% | 25.57% | 24.63% | 27.24% | 22.04% | 27.98% | Upgrade
|
| Advertising Expenses | - | 4.99 | 6.71 | 5.17 | 5.75 | 15.53 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.